Show simple item record

dc.contributor.authorGringeri, A.
dc.contributor.authorLassila, R.
dc.contributor.authorMorfini, M.
dc.contributor.authorNegrier, C.
dc.contributor.authorRocino, A.
dc.contributor.authorSchramm, W.
dc.contributor.authorSerban, M.
dc.contributor.authorUscatescu, M. V.
dc.contributor.authorWindyga, J.
dc.contributor.authorLeissinger, C.
dc.contributor.authorZulfikar, B.
dc.contributor.authorAntmen, B.
dc.contributor.authorBerntorp, E.
dc.contributor.authorBiasioli, C.
dc.contributor.authorCarpenter, S.
dc.contributor.authorKavakli, K.
dc.date.accessioned2021-03-06T12:36:19Z
dc.date.available2021-03-06T12:36:19Z
dc.date.issued2011
dc.identifier.citationGringeri A., Antmen B., Berntorp E., Biasioli C., Carpenter S., Kavakli K., Lassila R., Morfini M., Negrier C., Rocino A., et al., "The pro-FEIBA study: prophylactic dosing of Factor Eight Inhibitor Bypassing Activity (FEIBA) reduces bleeding frequency in haemophilia a patients with inhibitors", HAEMOPHILIA, cilt.17, ss.363, 2011
dc.identifier.issn1351-8216
dc.identifier.othervv_1032021
dc.identifier.otherav_f4a1c89a-3293-4d25-b48a-bd31f3912711
dc.identifier.urihttp://hdl.handle.net/20.500.12627/160364
dc.language.isoeng
dc.subjectHematoloji
dc.subjectHEMATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectHematology
dc.subjectHealth Sciences
dc.titleThe pro-FEIBA study: prophylactic dosing of Factor Eight Inhibitor Bypassing Activity (FEIBA) reduces bleeding frequency in haemophilia a patients with inhibitors
dc.typeMakale
dc.relation.journalHAEMOPHILIA
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume17
dc.identifier.issue2
dc.identifier.startpage363
dc.identifier.endpage363
dc.contributor.firstauthorID199860


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record